|
|
||||||||
EDITORIALS
Stuart C. Apfel and Douglas W. Zochodne
| You have reached the most complete version of this article accessible without further authentication.
More complete versions are available. Link to article |
Article topics:
This article has been cited by other articles:
![]() |
S Kuwabara, S Misawa, K Kanai, S Sawai, T Hattori, M Nishimura, and C Nakaseko Thalidomide reduces serum VEGF levels and improves peripheral neuropathy in POEMS syndrome J. Neurol. Neurosurg. Psychiatry, November 1, 2008; 79(11): 1255 - 1257. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Murillo Jr, J. E. Cox, and M. S. Oholendt An Overview of Chemotherapy-Induced Peripheral Neuropathy Journal of Pharmacy Practice, April 1, 2008; 21(2): 138 - 145. [Abstract] [PDF] |
||||
![]() |
R. Plasmati, F. Pastorelli, M. Cavo, E. Petracci, E. Zamagni, P. Tosi, D. Cangini, P. Tacchetti, F. Salvi, I. Bartolomei, et al. Neuropathy in multiple myeloma treated with thalidomide: A prospective study Neurology, August 7, 2007; 69(6): 573 - 581. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Mileshkin, R. Stark, B. Day, J. F. Seymour, J. B. Zeldis, and H. M. Prince Development of Neuropathy in Patients With Myeloma Treated With Thalidomide: Patterns of Occurrence and the Role of Electrophysiologic Monitoring J. Clin. Oncol., September 20, 2006; 24(27): 4507 - 4514. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Z. Badros, O. Goloubeva, A. P. Rapoport, B. Ratterree, N. Gahres, B. Meisenberg, N. Takebe, M. Heyman, J. Zwiebel, H. Streicher, et al. Phase II Study of G3139, a Bcl-2 Antisense Oligonucleotide, in Combination With Dexamethasone and Thalidomide in Relapsed Multiple Myeloma Patients J. Clin. Oncol., June 20, 2005; 23(18): 4089 - 4099. [Abstract] [Full Text] [PDF] |
||||
![]() |
Thalidomide Neuropathy: Does Dose Matter? Journal Watch Neurology, January 14, 2005; 2005(114): 8 - 8. [Full Text] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||